These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 36038347)

  • 1. [Analysis and significance of HBV DNA below the lower detection limit of HBV RNA levels after long-term NAs antiviral therapy in patients with hepatitis B virus cirrhosis].
    Wang CY; Cao Y; Feng YM; Li J; Jiang B; Zhang Y; Wen J; Zhu YJ; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2022 Jul; 30(7):758-762. PubMed ID: 36038347
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum HBV RNA is associated with liver fibrosis regression in HBeAg-positive chronic hepatitis B patients treated with nucleos(t)ide analogues.
    Bian D; Zhao J; Liao H; Wang Y; Ren Y; Jiang Y; Liu S; Chen X; Hu Z; Duan Z; Lu F; Zheng S
    J Viral Hepat; 2023 Apr; 30(4):303-309. PubMed ID: 36533536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues.
    Wang Y; Liao H; Deng Z; Liu Y; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Duan Z; Lu F; Zheng S
    J Viral Hepat; 2022 Jun; 29(6):420-431. PubMed ID: 35274400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of clinical characteristics of persistent HBeAg positivity in patients with chronic hepatitis B treated with nucleos(t)ide analogues].
    Peng LP; Gan WQ; Zheng YB; Chen YM; Liu J; Wu ZB; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2024 Mar; 32(3):193-200. PubMed ID: 38584099
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial.
    Yuen MF; Asselah T; Jacobson IM; Brunetto MR; Janssen HLA; Takehara T; Hou JL; Kakuda TN; Lambrecht T; Beumont M; Kalmeijer R; Guinard-Azadian C; Mayer C; Jezorwski J; Verbinnen T; Lenz O; Shukla U; Biermer M;
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):790-802. PubMed ID: 37442152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum hepatitis B virus pregenomic RNA profiles in patients with chronic hepatitis B on long-term antiviral therapy].
    Pan JL; Luo H; Zhang XX; Han YF; Chen HY; Zeng Z; Xu XY
    Zhonghua Gan Zang Bing Za Zhi; 2024 Jan; 32(1):16-21. PubMed ID: 38320786
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pronounced decline of serum HBsAg in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy.
    Wang ML; Chen EQ; Tao CM; Zhou TY; Liao J; Zhang DM; Wang J; Tang H
    Scand J Gastroenterol; 2017 Dec; 52(12):1420-1426. PubMed ID: 28880694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study.
    Xie Y; Zhu H; Guo Y; Ma Z; Qi X; Yang F; Mao R; Zhang J
    Can J Gastroenterol Hepatol; 2022; 2022():4325352. PubMed ID: 36531834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
    Demirören K; Kocamaz H; Doğan Y
    Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A study of the effectiveness of nucleos(t)ide analogues in the treatment of HBeAg- positive chronic hepatitis B with normal alanine aminotransferase and high level of HBV DNA].
    Wang FD; Zhou J; Zhang DM; Wang ML; Tao YC; Wu DB; Tang H; Chen EQ
    Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):389-394. PubMed ID: 35545563
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up.
    Cortese MF; Riveiro-Barciela M; Tabernero D; Rodriguez-Algarra F; Palom A; Sopena S; Rando-Segura A; Roade L; Kuchta A; Ferrer-Costa R; Quer J; Pacin B; Vila M; Casillas R; Garcia-Garcia S; Esteban R; Pumarola T; Buti M; Rodriguez-Frias F
    Microbiol Spectr; 2022 Apr; 10(2):e0214921. PubMed ID: 35377229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
    Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
    J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A randomized controlled study on factors influencing the curative effect of sequential combined interferon and lamivudine therapy in children with immune-tolerant phase chronic hepatitis B].
    Zhu SS; Dong Y; Zhang HF; Wang LM; Xu ZQ; Zhang M; Gan Y; Chen DW; Wang FC; Yan JG; Zhao P
    Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):604-609. PubMed ID: 31594077
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA.
    Wang J; Zhu L; Zhang S; Zhang Z; Fan T; Cao F; Xiong Y; Pan Y; Li Y; Jiang C; Yin S; Tong X; Xiong Y; Xia J; Yan X; Liu Y; Liu X; Chen Y; Li J; Zhu C; Wu C; Huang R
    Emerg Microbes Infect; 2024 Dec; 13(1):2339944. PubMed ID: 38584592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy.
    Papatheodoridi M; Papachristou E; Moschidis Z; Hadziyannis E; Rigopoulou E; Zachou K; Villeret F; Magiorkinis G; Lyberopoulou A; Gatselis N; Vlachogiannakos I; Manolakopoulos S; Dalekos GN; Zoulim F; Paraskevis D; Papatheodoridis GV
    J Viral Hepat; 2022 Nov; 29(11):948-957. PubMed ID: 35789515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
    Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
    [No Abstract]   [Full Text] [Related]  

  • 20. [A retrospective study on HBsAg clearance rate after antiviral therapy in children with HBeAg-positive chronic hepatitis B aged 1-7 years].
    Zhu SS; Dong Y; Xu ZQ; Wang LM; Chen DW; Gan Y; Wang FC; Yan JG; Cao LL; Wang P; Zhang HF
    Zhonghua Gan Zang Bing Za Zhi; 2016 Oct; 24(10):738-743. PubMed ID: 27938558
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.